A protein that evolved long before the human circulatory system may help unlock stronger cancer treatments. When C3 is ...

Scientists used CRISPR to make prostate cancer cells easier for the immune system to detect and destroy. The experimental ...

The ongoing multicentre, open-label study focuses on examining the safety, tolerability, and preliminary efficacy of DISP-10.

The parent of children with severe food allergies has said discovering oral immunotherapy treatment has been "life changing" ...

Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy determined ...

A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given before surgery ...

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced the first participant has been dosed in a Phase 1 ...

The world's first clinical trial of an experimental immunotherapy known as ZI-MA4-1 has begun after a British patient with ...

Accelerated approval targets a post–PD-1-refractory population with limited established options, encompassing unresectable advanced cutaneous melanoma after progression on prior PD-1–based therapy.

Explore emerging mechanisms of immune checkpoint inhibitor resistance in hepatocellular carcinoma (HCC) and how combination ...

A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to ...

Key Investor Takeaways ・Creative Medical Technology Holdings (NASDAQ:CELZ) received a Notice of Allowance from the U.S.